This invention relates to novel N-derivatives of 1-deoxy-nojirimyoin, to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.
This invention relates to novel N-derivatives of 1-deoxy-nojirimycin (1) to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.
wherein n is zero, one or two, and R is a glycosyl or etherified or acylated glycosyl radical containing from 1 to 3 hexose or pentose units, said glycosyl radical optionally bearing an ether or ester derivative of the hydroxyl moeity located on the anomeric carbon atom of the terminal hexose or pentose moeity.
本发明涉及 1-脱氧-野尻霉素(1)的新型 N 衍生物及其制备工艺和最终应用,特别是在糖尿病治疗中的应用。
其中 n 为 0、1 或 2,R 为含有 1 至 3 个己糖或戊糖单元的糖基或醚化或酰化的糖基,所述糖基任选带有位于末端己糖或戊糖单元的异构碳原子上的羟基的醚或酯衍生物。
New deoxynojirimycin derivatives as potent inhibitors of intestinal α-glucohydrolases
New N-alkyl, alkenyl and benzyl substituted DNJ derivatives incorporating a silicon atom in the substituent were synthesised. Kinetic parameters (K-i, t(1/2)) for inhibition of rat intestinal alpha-glucohydrolases as well as human lysosomal alpha-glucosidases were measured. New DNJ derivatives are potent and selective inhibitors of intestinal alpha-glucohydrolases. (C) 1997, Elsevier Science Ltd.